Figure 1 from CINSARC and Sarculator in Patients with Primary Retroperitoneal Sarcoma: A Combined Analysis of Single-Institution Data and the EORTC-STBSG-62092 Trial (STRASS)

Key Points

OS improved for patients with primary retroperitoneal sarcoma using CINSARC metrics.
DFS analysis indicates significant correlation with patient outcomes in the pooled cohort.
The study integrates data from a single institution and the EORTC-STBSG-62092 trial for a comprehensive perspective.
Findings suggest that CINSARC and Sarculator can enhance treatment strategies for sarcoma patients.

Combined analysis reports improved OS and DFS in primary retroperitoneal sarcoma, highlighting CINSARC's predictive potential.

OS (A) and DFS (B) curves in the pooled cohort according to CINSARC.

No takes yet. Share an insight, caveat, or question.

Callegaro et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share